CN102423309B - Drug composition for treating vomiting - Google Patents
Drug composition for treating vomiting Download PDFInfo
- Publication number
- CN102423309B CN102423309B CN 201110407799 CN201110407799A CN102423309B CN 102423309 B CN102423309 B CN 102423309B CN 201110407799 CN201110407799 CN 201110407799 CN 201110407799 A CN201110407799 A CN 201110407799A CN 102423309 B CN102423309 B CN 102423309B
- Authority
- CN
- China
- Prior art keywords
- vomiting
- parts
- drug composition
- stomach
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention discloses a drug composition for treating vomiting. The drug composition comprises the following components, wherein the components comprise, by weight, 1 part of succinic acid, 7 parts of malic acid, 10 parts of citric acid, 0.3 part of linoleic acid, 2.3 parts of 6-shogaol and 7 parts of 6-gingerol. With the drug composition of the present invention, various vomiting can be effectively treated.
Description
Technical field
The invention belongs to drug world, be specifically related to a kind of pharmaceutical composition for the treatment of vomiting.
Background technology
Vomiting is the disease that clinical common phenomenon, particularly Patients Receiving Chemotherapy cannot be avoided, and a lot of patients are postoperative vomiting and have to abandon chemotherapy or radiotherapy for fear often, thereby delays the state of an illness.Although it is many to be used for the treatment of at present the medicine of vomiting, but effect is unsatisfactory, although resemble ondansetron, this class medicine of granisetron has certain effect to emesis of chemotherapy, because these drug prices are expensive and certain side effect is arranged, also limited to a certain extent their use.
Vomiting belongs to " QI rising in reverse order " category in Chinese medicine, motherland's traditional medicine thinks that vomiting is because stomach-QI being unable to descend normally, adverse rising of stomach-QI are caused, and the treatment vomiting should be with regulating functional activities of qi, and stopping nausea and vomiting by lowering the adverse flow of QI is main.Chinese medicine has the irreplaceable advantage of chemical synthetic drug, low price, and toxic and side effects is little.The hot loose warm-dryness syndrome of the Rhizoma Pinelliae, the master enters spleen, stomach, lung meridian, and the water of manageing it is wet, lowering the adverse flow of QI, merit is apt to the dampness stopping nausea and vomiting by lowering the adverse flow of QI, cures mainly nausea and vomiting, cold syndrome of the stomach and the vomiting due to fluid-retention etc. of adverse rising of stomach-QI.The Rhizoma Zingiberis Recens acrid in the mouth is warm in nature, returns spleen, stomach, lung meridian, the preventing or arresting vomiting that can whet the appetite, and relieving the exterior syndrome by diaphoresis can be treated the vomiting due to nausea and vomiting, vomiting due to fluid-retention and the disorder of stomach-QI due to the Deficiency and coldness of spleen and stomach.Modern study shows that organic acid composition contained in the Rhizoma Pinelliae has preferably pharmacologically active; 6-gingerol in the Rhizoma Zingiberis Recens, 6-shogaol class material are main active wherein.
On the tcm clinical practice, often with the Rhizoma Pinelliae, Rhizoma Zingiberis Recens compatibility, form Chinese medicine compound and be used for the treatment of the vomiting that a variety of causes causes, evident in efficacy.But traditional Chinese medicine compound exists into to be hard to tell, and mechanism is not clear, the difficult control of quality, the shortcoming of curative effect shakiness.
Summary of the invention
Technical problem to be solved by this invention provides a kind of pharmaceutical composition for the treatment of vomiting, said composition definite ingredients, stable curative effect.
For solving the problems of the technologies described above, the technical solution used in the present invention is as follows:
A kind of pharmaceutical composition for the treatment of vomiting, it is comprised of the component of following parts by weight:
1 part of succinic acid;
7 parts of hydroxyl succinic acid;
10 parts of citric acids;
0.3 part of linoleic acid;
2.3 parts of (E)-1-(4-hydroxy-3-methoxyphenyl)dec-4-en-3-ones (6-shogaol);
7 parts of 6-gingerols (6-gingerol).
Above-mentioned active component can extract or preparation by prior art, also can directly buy from the market.
Above-mentioned active component can prepare the pharmaceutical composition for the treatment of vomiting according to the simple mixing of formula ratio.
The application of aforementioned pharmaceutical compositions in preparation treatment vomiting medicine.
Beneficial effect: the invention has the advantages that each constituent is simple and easy to, cheap, each composition all derives from the wholefood, and side effect is very little, and pharmacological evaluation confirmation drug effect is remarkable, has good resisting emesis effect.Can be used for treating the vomiting that many reasons causes.
The specific embodiment
According to following embodiment, the present invention may be better understood.Yet, those skilled in the art will readily understand that embodiment is described only to be used for explanation the present invention, and should also can not limit the present invention described in detail in claims.
Embodiment 1:
A kind of pharmaceutical composition for the treatment of vomiting, it is made by the component mix homogeneously of following parts by weight:
1 part of succinic acid;
7 parts of hydroxyl succinic acid;
10 parts of citric acids;
0.3 part of linoleic acid;
2.3 parts of (E)-1-(4-hydroxy-3-methoxyphenyl)dec-4-en-3-ones;
7 parts of 6-gingerols.
Experimental example 2: the present composition is to the pharmacological action of vomiting treatment.
One, on the impact of rat pica behavior.
1. experiment material
1.1 sample, the 1. pharmaceutical composition that makes of embodiment 1 faces the time spent to be mixed with certain density solution.Compound method: it is an amount of to get this pharmaceutical composition, accurately weighed, adds a certain amount of 0.5%CMC-Na, and ultrasonic 10min stirs, till abundant suspendible; 2. ondansetron inj (specification: 4mL8mg
-1Lot number: 9090111EH; Shandong Qilu Pharmaceutical Co., Ltd.).
1.2 reagent, 1. cisplatin (injectable powder; Specification: 10mg; Lot number: 9110271DB; Shandong Qilu Pharmaceutical Co., Ltd.); 2. Kaolin (analytical pure, preparation mixes Kaolin with reference to the method for Takeda N etc. with 1% arabic gum, make the granule similar to animal feed); 3. CMC-Na, analytical pure.
1.3 animal, SD rat, body weight 260～300g, male and female dual-purpose, Shanghai Slac Experimental Animal Co., Ltd. (SCXK (Shanghai) 2007-0005).Raise in Nanjing University of Traditional Chinese Medicine's Animal House constant temperature (24 ± 1 ℃) constant humidity (50 ± 5%) receptacle, light/dark cycle is 12/12h (light application time is 7:00-19:00), ad lib, drinking-water.
1.4 instrument, Sartorius BP211D type electronic balance (one thousandth).
2. method and result
Healthy rat list cage is raised, and at first adaptability was raised 3 days, treat that animal conforms after, in feedstuff, add Kaolin, observe rat to the kaolinic situation of ingesting, after 3 days, reject those and do not take in Kaolin and rat very curious to Kaolin, a large amount of absorptions.
With all the other qualified rat random packet (after general 3 days, the Kaolin that rat is taken in is very micro-), 8 every group (still raising separately for every).
Administration: normal group and model group: the capacity 0.5%CMC-Na (10mLkg such as gavage
-1); Positive drug group: lumbar injection ondansetron 0.8mgkg
-1Compositions group (2 groups): gavage 2mgkg
-1, 4mgkg
-1
Successive administration was tested later in 5 days, tested the same day, normal administration, and after the 1h, except normal group, all the other respectively organize equal lumbar injection cisplatin 5mgkg
-1, the record rat is taken in the amount of Kaolin and food behind the 24h.
Data with
The SPSS13.0 statistical software is adopted in expression, variance analysis, and P＜0.05 is for there being significant difference.The results are shown in Table 1.
Table 1 present composition is on the impact of rat pica due to the cisplatin
Annotate: compare with model group,
*P＜0.05
The result shows that after the rats by intraperitoneal injection cisplatin, the intake of kaolin obviously increases; The high low dose group of the present composition all can obviously reduce the increase of the rat Kaolin intake due to the cisplatin, compares with model group, and significant difference (P＜0.05) is arranged; After the lumbar injection cisplatin, the food-intake of rat obviously reduces; Compare with model group, the present composition can obviously increase the food-intake (P＜0.05) of rat; Compare present composition group unknown significance difference (P＞0.05) with positive drug ondansetron group.
Two, on the impact of cisplatin induced mice gastric emptying.
1. experiment material
1.1 sample, the 1. pharmaceutical composition that makes of embodiment 1 faces the time spent to be mixed with certain density solution.Compound method: it is an amount of, accurately weighed to get said composition, adds a certain amount of 0.5%CMC-Na, and ultrasonic 10min stirs, till abundant suspendible; 2. ondansetron inj (specification: 4mL8mg
-1Lot number: 9090111EH; Shandong Qilu Pharmaceutical Co., Ltd.);
1.2 reagent, cisplatin (injectable powder; Specification: 10mg; Lot number: 9110271DB; Shandong Qilu Pharmaceutical Co., Ltd.); Phenol red (the Solution on Chemical Reagents in Shanghai purchasing and supply station, 86-12-17); NaHCO
3, CMC-Na, be analytical pure.
1.3 animal, ICR mice, body weight 18～22g, male and female dual-purpose, Shanghai Slac Experimental Animal Co., Ltd. (SCXK (Shanghai) 2007-0005).Raise in Nanjing University of Traditional Chinese Medicine's Animal House constant temperature (24 ± 1 ℃) constant humidity (50 ± 5%) receptacle, light/dark cycle is 12/12h (light application time is 7:00-19:00), ad lib, drinking-water.
1.4 instrument: SPECTRA MAX 190 UV, visible light microwell plate detectors (U.S. MOLECULAR DEVICES); GS-15R type tabletop refrigerated centrifuge (U.S. BECKMAN company); PHs series pH meter (Lida Instrument Factory, Shanghai).
2. method and result
Get healthy mice, male and female half and half, random packet, 10 every group.Normal group and model group, the capacity 0.5%CMC-Na (10mLkg such as gavage
-1); The positive drug group, lumbar injection ondansetron 1.2mgkg
-1Compositions (2 groups), gavage 3.5mgkg
-1, 7.0mgkg
-1
Successive administration 5 days, water 12h is can't help in fasting before last administration.Test the same day, 1h after the administration, except normal group, all the other respectively organize equal lumbar injection cisplatin 7mgkg
-1, after 40 minutes, every mouse stomach 0.04% phenol red solution 0.2mL puts to death behind the 15min, gets the small beaker that stomach places the 5mL distilled water, cuts off stomach with eye scissors along greater gastric curvature, and gastric content is fully washed in distilled water, uses NaHCO
3Solution is regulated pH value to 6.0-6.5, gets supernatant with 12000rmin
-1Centrifugal 3min, the accurate supernatant 200 μ L that draw measure light absorption value (wavelength 560nm) with microplate reader in 96 orifice plates.The light absorption value that records is phenol red light absorption value residual in the stomach.The height of phenol red residual rate can reflect the speed of gastric emptying.
Stomach residue rate (%)=(the phenol red optical density of phenol red optical density/benchmark in the stomach) * 100%
Data with
The SPSS13.0 statistical software is adopted in expression, variance analysis, and P＜0.05 is for there being significant difference.Experimental result sees Table 2.
Table 2 present composition is on the impact of cisplatin induced mice gastric emptying
Annotate: compare with model group,
*P＜0.05.
The result shows that after the lumbar injection cisplatin, the gastric residual rate of mice significantly raises; The high low dose group of the present composition all can obviously be resisted the emptying inhibition of Mouse Stomach due to the cisplatin, compares with model group, and the gastric residual rate of each group significantly reduces; The effect of the present composition is compared with positive drug ondansetron group, does not have significant difference.
Claims (2)
1. pharmaceutical composition for the treatment of vomiting is characterized in that it is comprised of the component of following parts by weight:
2. the application of pharmaceutical composition claimed in claim 1 in preparation treatment vomiting medicine, wherein, described vomiting is the vomiting that chemotherapeutics brings out.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110407799 CN102423309B (en) | 2011-12-09 | 2011-12-09 | Drug composition for treating vomiting |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110407799 CN102423309B (en) | 2011-12-09 | 2011-12-09 | Drug composition for treating vomiting |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102423309A CN102423309A (en) | 2012-04-25 |
| CN102423309B true CN102423309B (en) | 2013-01-16 |
Family
ID=45957400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110407799 Expired - Fee Related CN102423309B (en) | 2011-12-09 | 2011-12-09 | Drug composition for treating vomiting |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102423309B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1615146A (en) * | 2001-11-26 | 2005-05-11 | 芬策尔贝格有限两合公司 | Ginger extract preparation |
| CN1887340A (en) * | 2005-06-28 | 2007-01-03 | 陈依侬 | Cinesia treating medicine composition |
-
2011
- 2011-12-09 CN CN 201110407799 patent/CN102423309B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1615146A (en) * | 2001-11-26 | 2005-05-11 | 芬策尔贝格有限两合公司 | Ginger extract preparation |
| CN1887340A (en) * | 2005-06-28 | 2007-01-03 | 陈依侬 | Cinesia treating medicine composition |
Non-Patent Citations (4)
| Title |
|---|
| 吴皓等.药典法姜半夏与正交法姜半夏药理作用的比较.《中成药》.1998,第20卷(第4期),第16-18和50-51页. |
| 姜辣素在2种呕吐动物模型中止呕作用机制的探讨;王耀霞等;《沈阳药科大学学报》;20090228;第26卷(第2期);第134-137和164页 * |
| 王耀霞等.姜辣素在2种呕吐动物模型中止呕作用机制的探讨.《沈阳药科大学学报》.2009,第26卷(第2期),第134-137和164页. |
| 药典法姜半夏与正交法姜半夏药理作用的比较;吴皓等;《中成药》;19981231;第20卷(第4期);第16-18和50-51页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102423309A (en) | 2012-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102145062B (en) | Active extracts of rosa roxburghii tratt fruit, and preparation method, detection method and application thereof | |
| Rahman et al. | Anti-inflammatory, antinociceptive and antidiarrhoeal activities of methanol and ethyl acetate extract of Hemigraphis alternata leaves in mice | |
| Younis et al. | Effect of zinc as an add-on to metformin therapy on glycemic control, serum insulin, and c-peptide levels and insulin resistance in type 2 diabetes mellitus patient | |
| Xu et al. | Evaluation of safety of iridoids rich fraction from Valeriana jatamansi Jones: Acute and sub-chronic toxicity study in mice and rats | |
| CN103110023A (en) | Feed Chinese herbal medicine additive for improving broiler chicken immunity and production method thereof | |
| CN101606908B (en) | Decoquinate soluble powder and preparation method thereof | |
| CN1895421B (en) | Chinese animal medicine for improving fowl growth | |
| CN103623134B (en) | A kind of Chinese medicine preparation preventing and treating Salmonella pullorum disease and preparation method thereof | |
| CN102423309B (en) | Drug composition for treating vomiting | |
| RYU et al. | Effects of Job's tear (Yul-Moo) extracts on mouse immune cell activation | |
| CN104906179A (en) | Origanum oil suspension and preparation method thereof | |
| CN103610060B (en) | Method for preparing VC (vitamin C) hovenia acerba hangover alleviation chewable tablets | |
| Sathyanath et al. | Saponin and non-saponin fractions of red ginseng ameliorate cisplatin-induced pica in rats | |
| US20200330374A1 (en) | Rectal mucosal administration preparation of pulsatilla chinensis saponin b4 and preparation method therefor | |
| Wang et al. | Regulatory effects of Ningdong granule on dopaminergic and serotonergic neurotransmission in a rat model of Tourette syndrome assessed by PET | |
| Lü et al. | Phenolic profiles, antioxidant activity and inhibition of digestive enzymes of water caltrop pericarps | |
| Shi | Evaluating the various phases of cisplatin‑induced emesis in rats | |
| CN114452344A (en) | Preparation method of Kaixin powder | |
| CN103622986A (en) | Anti-stress balance regulator composition for livestock and poultry as well as preparation method and application of composition | |
| Niu et al. | Effect of Malus halliana Koehne polysaccharides on functional constipation | |
| Garrido‐Suárez et al. | Antihyperalgesic effects of an aqueous stem bark extract of Mangifera indica L.: role of mangiferin isolated from the extract | |
| CN100500136C (en) | Effervescence tablet with honeysuckle, Chinese gold thread and forsythia fruit | |
| CN102727596B (en) | A kind of Chinese herbal granules for preventing chicken coccidiasis and preparation method thereof | |
| GALKINA et al. | Arrhenius kinetics in the evaluation of the biological activity of pharmaceutical tinctures | |
| CN101983649A (en) | Method for preparing traditional Chinese medicine tincture for curing leucoderma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130116 Termination date: 20201209 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |